natgillin/translations-raw huggingface dataset:
In 44 patients with schizophrenia >65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events. 
U 44 bolesnika sa shizofrenijom, u dobi od 65 godina, doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim razlikovnim profilom štetnih događaja.
Olanzapine Teva with alcohol 
Olanzapin Teva s alkoholom
mixed liver injury)11 
mješovito oštećenje jetre) 11
1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. 
Klinički značajno povećanje tjelesne težine uočeno je u svim početnim kategorijama indeksa tjelesne mase (BMI).
What Olanzapine Teva looks like and contents of the pack 
Kako Olanzapin Teva izgleda i sadržaj pakiranja
What Olanzapine Teva is and what it is used for 
Što je Olanzapin Teva i za što se koristi
Other medicines and Olanzapine Teva 
Drugi lijekovi i Olanzapin Teva
It is important that you carry on taking Olanzapine Teva for as long as your doctor tells you. 
Važno je da nastavite uzimati Olanzapin Teva onoliko dugo koliko Vam je liječnik rekao.
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10). 
Navedene učestalosti definirane su kako slijedi: vrlo često (≥1/10), često (≥1/100 do <1/10).
You can also place the tablet in a full glass or cup of water, orange juice, apple juice, milk or coffee, and stir. 
Tabletu također možete ubaciti u čašu ili šalicu punu vode, soka od naranče ili jabuke, mlijeka ili kave te promiješati.
The frequency terms listed are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the data available). 
Učestalost je definirana kako slijedi: vrlo često (≥1/10), često (≥1/100 do <1/10), manje često (≥1/1000 do <1/100), rijetko (≥1/10 000 do <1/1000), vrlo rijetko (<1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months. 
odraslih bolesnika koji su nakon 9-12 mjeseci završili liječenje, brzina povećanja vrijednosti glukoze u krvi smanjila se nakon otprilike 6 mjeseci.
Swensweg 5, 2031 GA Haarlem, The Netherlands 
Swensweg 5, 2031 GA Haarlem, Nizozemska
Clinically significant weight gain (≥7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. 
Čini se da se klinički značajno povećanje tjelesne težine (≥7%) češće javlja u populaciji adolescenata u usporedbi s odraslim osobama s usporedivim izlaganjima lijeku.
Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration. 
Alternativno se može rastopiti u čaši punoj vode ili nekog drugog prikladnog napitka (soka od naranče, soka od jabuke, mlijeka ili kave)
Dystonia (including oculogyration)11 
Distonija (uključujući okulogiraciju)11
- Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria. 
• Umjerenih do blagih epizoda manije, stanja sa simptomima uzbuđenja ili euforije.
Olanzapine is bound predominantly to albumin and α1-acid-glycoprotein. 
Olanzapin se prvenstveno veže na albumin i α1-acidni-glikoprotein.
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients. 
16 Povišene razine prolaktina u plazmi zabilježene su u 47,4% adolescentnih bolesnika.
Risk Management Plan (RMP) Not applicable. 
LIJEKA • Plan upravljanja rizikom (RMP)
Abdominal distension9 
Abdominalna distenzija9
Discontinuation symptoms7,12 
Simptomi ustezanja7,12
The daily dose of Olanzapine Teva is between 5 mg and 20 mg. 
Dnevna doza Olanzapina Teva iznosi između 5 mg i 20 mg.
In patients with Parkinson's disease Olanzapine Teva may worsen the symptoms. 
U bolesnika koji boluju od Parkinsonove bolesti, Olanzapin Teva može pogoršati simptome.
LIST OF EXCIPIENTS Contains, among others, Lactose monohydrate. 
POPIS POMOĆNIH TVARI Između ostalog sadrži laktozu hidrat.
Teva Pharmaceutical Works Co. Ltd Pallagi út 13, 4042 Debrecen Hungary 
Ltd Pallagi út 13, 4042 Debrecen
Ventricular tachycardia/fibrill ation, sudden death (see section 4.4)11 
Ventrikularna tahikardija/ fibrilacija, iznenadna smrt (vidjeti dio 4.4)11
- carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olanzapine Teva dose. 
• karbamazepin (antiepileptik i stabilizator raspoloženja), fluvoksamin (antidepresiv) ili ciprofloksacin (antibiotik) - možda će biti potrebno promijeniti dozu Olanzapina Teva.
Orodispersible tablet is the technical name for a tablet which dissolves directly in your mouth, so that it can be easily swallowed. 
Raspadljiva tableta za usta je stručni naziv za tabletu koja se otapa izravno u ustima pa se tako može lako progutati.
What you need to know before you take Olanzapine Teva 
Što morate znati prije nego počnete uzimati Olanzapin Teva
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Teva in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. 
Sljedeći simptomi mogu se pojaviti u novorođenčadi majki koje su koristile Olanzapin Teva u posljednjem tromjesečju (zadnja tri mjeseca trudnoće): drhtanje, ukočenost mišića i/ili slabost, pospanost, uznemirenost, problemi s disanjem te poteškoće u hranjenju.
Date of latest renewal: 12. 
Datum posljednje obnove odobrenja: 12. prosinca 2012.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki <100 nM) for serotonin 
U pretkliničkim ispitivanjima, olanzapin je pokazao raspon afiniteta za receptore (Ki <100 nM)
Do not take Olanzapine Teva: - if you are allergic to olanzapine or any of the other ingredients of this medicine (listed in section 6). 
- ako ste alergični na olanzapin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Olanzapine administered with lithium or valproate resulted in increased levels (≥10%) of tremor, dry mouth, increased appetite, and weight gain. 
Olanzapin primijenjen s litijem ili valproatom rezultirao je povećanim razinama (≥10%) tremora, suhoće usta, povećanjem apetita i povećanjem tjelesne težine.
Hypersensitivity11 
Hipersenzitivnost11
Pancreatitis11 
Pankreatitis11
With some drinks, the mixture may change colour and possibly become cloudy. 
Kada se pomiješa s nekim napicima, tekućina može promijeniti boju ili se zamutiti.
The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng/ml. 
Vezanje olanzapina na proteine u plazmi bilo je oko 93% preko raspona koncentracije od oko 7 do oko 1000 ng/ml.
Pharmacotherapeutic group: psycholeptics, diazepines, oxazepines, thiazepines and oxepines. 
Farmakoterapijska skupina: psiholeptici, diazepini, oksazepini, tiazepini i oksepini.
If you take more Olanzapine Teva than you should Patients who have taken more Olanzapine Teva than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. 
Bolesnici koji su uzeli više Olanzapina Teva nego što su trebali imaju sljedeće simptome: ubrzani rad srca, uznemirenost/agresivnost, problemi s govorom, neuobičajeni pokreti (osobito lica ili jezika) i snižena razina svijesti.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Teva unless your doctor tells you to. 
posavjetujte se sa svojim liječnikom, ali nemojte prestati uzimati Olanzapin Teva dok Vam liječnik to ne kaže.
Urinary incontinence Urinary retention Urinary hesitation11 
Urinarna inkontinencija Urinarna retencija Otežano mokrenje11
Elevated triglyceride levels2,5 
Povišene razine triglicerida2,5
This medicine contains 2.25 mg/4.5 mg/6.75 mg/9 mg aspartame in each 5 mg/10 mg/15 mg/20 mg orodispersible tablet. 
Ovaj lijek sadrži 2,25 mg/4,5 mg/6,75 mg/9 mg aspartama u jednoj raspadljivoj tableti za usta od 5 mg/10 mg/15 mg/20 mg.
Age >75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment. 
Dob starija od 75 godina i demencija vaskularnog/miješanog tipa bili su prepoznati kao čimbenici rizika za CV štetne događaje povezane s liječenjem olanzapinom.
In addition, the 15 mg strength contains indigo carmine (E132) and the 20 mg strength contains iron oxide red (E172). 
Osim toga, tableta od 15 mg sadrži indigo carmine (E132), a tableta od 20 mg sadrži željezov oksid, crveni (E172).
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported. 
U istim kliničkim ispitivanjima zabilježeni su cerebrovaskularni štetni događaji (CV štetni događaji, primjerice moždani udar, prolazni ishemijski napad) uključujući smrtne slučajeve.
You should not be given this medicine when breast-feeding, as small amounts of Olanzapine Teva can pass into breast milk. 
Ne smijete primati Olanzapin Teva dok dojite, jer se male količine ovog lijeka mogu izlučiti u majčino mlijeko.
DRESS appears initially as flu like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia). 
DRESS se na početku očituje simptomima nalik gripi s osipom po licu, a kasnije i proširenim osipom, visokom temperaturom, povećanim limfnih čvorovima, povišenim razinama jetrenih enzima koji su vidljivi u krvnim pretragama te povećanjem broja jedne vrste bijelih krvnih stanica (eozinofilija).
In most of these cases, a history of seizures or risk factors for seizures were reported. 
U većini ovih slučajeva zabilježeni su u anamnezi napadaji ili čimbenici rizika za nastanak napadaja.
Neuroleptic malignant syndrome (see section 4.4)12 
Neuroleptički maligni sindrom (vidjeti dio 4.4)12
In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p= 0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1). 
U multinacionalnom, dvostruko slijepom, komparativnom ispitivanju shizofrenije, shizoafektivnih i povezanih poremećaja, koje je obuhvaćalo 1481 bolesnika s različitim stupnjevima pridruženih simptoma depresije (prosječna vrijednost 16,6 po Montgomery-Asberg ljestvici depresije), prospektivna sekundarna analiza vrijednosti promjene raspoloženja od početnog do krajnjeg pokazala je statistički značajno poboljšanje (p= 0,001) u korist olanzapina (-6,0) u odnosu na haloperidol (-3,1).
Very common symptoms in overdose (>10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma. 
Vrlo česti simptomi predoziranja (incidencija >10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and <0.1%) when olanzapine is stopped abruptly. 
Prekid liječenja Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su rijetko zabilježeni (≥0.01% i <0,01%) nakon naglog prekida uzimanja olanzapina.
Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo-controlled clinical trials (see section 4.8). 
Neželjene promjene vrijednosti lipida uočene su u bolesnika liječenih olanzapinom u placebo kontroliranim kliničkim ispitivanjima (vidjeti dio 4.8).
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥7% from baseline body weight in 39.9% of patients. 
Dugotrajno liječenje olanzapinom (do 12 mjeseci) zbog prevencije relapsa u bolesnika s bipolarnim poremećajem bilo je povezano s povećanjem tjelesne težine ≥7% od početne tjelesne težine u 39,9% bolesnika.
If you stop taking Olanzapine Teva 
Ako prestanete uzimati Olanzapin Teva
Contains among others: lactose, sucrose and aspartame (E951). 
Između ostalog sadrži: laktozu, saharozu i aspartam (E951).
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels. 
U jednom kliničkom ispitivanju u bolesnika s bipolarnom manijom, kombinacijska terapija valproata i olanzapina uzrokovala je incidenciju neutropenije od 4,1%; mogući faktor koji je tome pridonio mogle su biti visoke razine valproata u plazmi.
Dizziness Akathisia6 
Omaglica Akatizija6
- The use of Olanzapine Teva in elderly patients with dementia is not recommended as it may have serious side effects. 
- Primjena Olanzapina Teva u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
Olanzapine Teva orodispersible tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed. 
Olanzapin Teva raspadljivu tabletu za usta treba staviti u usta, gdje se brzo rastapa u slini te se može lako progutati.
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure. 
Povećanje tjelesne težine i omjer adolescentnih bolesnika koji su imali klinički značajno povećanje tjelesne težine bili su veći tijekom dugotrajnog izlaganja (najmanje 24 tjedana)
Tardive dyskinesia11 Amnesia9 
Tardivna diskinezija11 Amnezija 9
Metabolism and nutrition disorders Weight gain1 
Poremećaji metabolizma i prehrane Povećanje tjelesne težine1
Olanzapine Teva has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment. 
Pokazalo se da Olanzapin Teva sprječava ponavljanje tih simptoma u bolesnika s bipolarnim poremećajem čije su epizode manije reagirale na liječenje olanzapinom.
Do not drink any alcohol if you have been given Olanzapine Teva as together with alcohol it may make you feel drowsy. 
Nemojte piti alkohol tijekom uzimanja Olanzapina Teva, jer u kombinaciji s alkoholom može Vam izazvati pospanost.
- Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. 
- Vrlo rijetko, lijekovi ovog tipa uzrokuju kombinaciju vrućice, ubrzanog disanja, znojenja, ukočenosti mišića te omamljenosti ili pospanosti.
However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE, e.g. immobilisation of patients, should be identified and preventive measures undertaken. 
Međutim, budući da bolesnici sa shizofrenijom često imaju stečene čimbenike rizika za vensku tromboemboliju, sve moguće čimbenike rizika za VTE npr. imobilizacija bolesnika,
≥25% was common (2.5%). 
(7,1%), a ≥25% bio je čest (2,5%).
Elevated cholesterol levels2,3 
Povišene razine kolesterola2,3
Merckle GmbH Ludwig-Merckle-Strasse 3, 89143 Blaubeuren, Germany 
Merckle GmbH Ludwig-Merckle-Strasse 3, 89143 Blaubeuren,
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value. 
8 U kliničkim ispitivanjima u trajanju do 12 tjedana, koncentracije prolaktina u plazmi prelazile su gornju granicu normalnog raspona u približno 30% bolesnika liječenih olanzapinom s normalnom početnom vrijednosti prolaktina.
Mean infant exposure (mg/kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/kg). 
Prosječna izloženost novorođenčeta (mg/kg) u stanju dinamičke ravnoteže procijenjena je na 1,8% majčine doze olanzapina
Hypothermia12 
Hipotermija12
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 12. 
DATUM PRVOG ODOBRENJA / DATUM OBNOVE ODOBRENJA
The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non-smokers and 77% in male smokers. 
Srednja vrijednost porasta Cmax olanzapina, nakon primjene fluvoksamina, iznosila je 54% u žena nepušača i 77% u muškaraca pušača.
Eastbourne, East Sussex, BN22 9AG United Kingdom 
Eastbourne, East Sussex, BN22 9AG Ujedinjeno Kraljevstvo
Parkinsonism6 Dyskinesia6 
Parkinsonizam6 Diskinezija6
A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4). 
Niža početna doza (5 mg/dan) nije rutinski indicirana, no treba ju razmotriti u osoba u dobi od 65
5HT2A/2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1 M5; α1 adrenergic; and histamine H1 receptors. 
serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore
In renally impaired patients (creatinine clearance <10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr). 
U bolesnika s oštećenjem bubrega (klirens kreatinina <10 ml/min) nije bilo značajne razlike u odnosu na zdrave ispitanike u srednjoj vrijednosti poluvremena eliminacije (37,7 u odnosu na 32,4 sata) ili klirensu (21,2 u odnosu na 25,0 l/sat).
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks). 
Tijekom liječenja olanzapinom u kombinaciji s litijem ili divalproeksom, porast tjelesne težine ≥7% od početne pojavio se u 17,4% bolesnika tijekom akutnog liječenja (do 6 tjedana).
You should swallow the Olanzapine Teva tablets whole with water. 
Olanzapin Teva tablete trebate progutati cijele s vodom.
In placebocontrolled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementiarelated psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively). 
U placebom kontroliranim kliničkim ispitivanjima (trajanja od 6 do 12 tjedana) starijih bolesnika (srednja vrijednost dobi 78 godina) s psihozom i/ili poremećajima ponašanja uzrokovanih demencijom zabilježeno je dvostruko povećanje incidencije smrtnosti u bolesnika liječenih olanzapinom u usporedbi s bolesnicima koji su primali placebo (3,5% u odnosu na 1,5%).
It may be harmful for patients with phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly. 
Može biti štetno za bolesnike s fenilketonurijom, rijetkim genetskim poremećajem kod kojeg dolazi do nakupljanja fenilalanina jer ga tijelo ne može ukloniti na odgovarajući način.
Increased alkaline phosphatase10 
Povišena alkalna fosfataza10
Olanzapine Teva tablets break easily, so you should handle the tablets carefully. 
Olanzapin Teva tablete lako se lome te s njima treba pažljivo rukovati.
High creatine phosphokinase11 
Visoka kreatin fosfokinaza11
Olanzapine demonstrated a greater in vitro affinity for serotonin 5HT2 than dopamine D2 receptors and greater 5HT than D activity in vivo models. 
Olanzapin je in vitro pokazao veći afinitet za serotoninske 5HT2 nego dopaminske D2 receptore te veće djelovanje na 5HT nego
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5HT2A than dopamine D2 receptor occupancy. 
U ispitivanju pomoću pozitronske emisijske tomografije (PET), jednostruka oralna doza (10 mg) olanzapina u zdravih dobrovoljaca dovela je do većeg zauzimanja 5HT2A nego dopaminskih D2 receptora.
SPECIAL STORAGE CONDITIONS Store in the original package in order to protect from light. 
POSEBNE MJERE ČUVANJA Čuvajte u originalnom pakiranju radi zaštite od svjetlosti.
Olanzapine Teva film-coated tablets contain lactose. 
Olanzapin Teva filmom obložene tablete sadrže laktozu.
Gastrointestinal disorders Mild, transient anticholinergic effects including constipation and dry mouth 
Blagi, prolazni antikolinergički učinci uključujući konstipaciju i suha usta
There were more smokers among subjects with cirrhosis (4/6; 67%) than among subjects with no hepatic dysfunction (0/3; 0%). 
(4/6, 67%) nego među ispitanicima koji nisu imali disfunkciju jetre (0/3, 0%).
With long-term exposure (at least 24 weeks), 89.4% gained ≥7%, 55.3%gained ≥15% and 29.1% gained ≥25% of their baseline body weight. 
Tijekom dugotrajne izloženosti (najmanje 24 tjedna), u 89,4% bolesnika povećala se tjelesna težina ≥7%, u 55,3% ≥15%, a u 29,1% bolesnika tjelesna težina se povećala ≥25% od njihove tjelesne težine na početku liječenja.
In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥500 milliseconds [msec] at any time post baseline in patients with baseline QTcF <500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. 
U kliničkim ispitivanjima, klinički značajna produljenja QTc (Fridericia QT korekcija [QTcF] ≥500 milisekundi [msek] bilo kada nakon početne vrijednosti u bolesnika s početnom vrijednošću QTcF<500 milisekundi) bila su manje česta (0,1% do 1%) u bolesnika liječenih olanzapinom, bez značajnih razlika u povezanim kardijalnim događajima u usporedbi s placebom.
If this happens after you have been given Olanzapine Teva tell your doctor. 
Ako Vam se ovo pojavi nakon uzimanja Olanzapina Teva, obratite se svom liječniku.
A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2). 
Kratkotrajna ispitivanja provedena na adolescentima zabilježila su veće povećanje tjelesne težine i veće promjene vrijednosti lipida i prolaktina nego ispitivanja provedena na odraslim bolesnicima (vidjeti dijelove 4.4, 4.8, 5.1 i 5.2).
Olanzapine orodispersible tablet is bioequivalent to olanzapine coated tablets, with a similar rate and extent of absorption. 
Olanzapin raspadljiva tableta za usta je bioekvivalent tabletama olanzapina, sa sličnom brzinom i opsegom apsorpcije.
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p = 0.055). 
U drugom 12-mjesečnom ispitivanju prevencije relapsa epizode manije, bolesnici koji su postigli remisiju kombinacijom olanzapina i litija te su potom bili randomizirani u skupinu koja je primala samo olanzapin ili samo litij, olanzapin nije bio statistički inferioran litiju u pogledu primarnog ishoda relapsa bipolarnog poremećaja (olanzapin 30,0%, litij 38,3%; p=0,055).
Very common: Weight gain13, elevated triglyceride levels14, increased appetite. 
Poremećaji metabolizma i prehrane Vrlo često: Povećanje tjelesne težine13, povišene razine triglicerida14, povećani apetit.
Bradycardia QTc prolongation (see section 4.4) 
Bradikardija produljenje QTc intervala (vidjeti dio 4.4)